The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JBIO | +14.3% | N/A | N/A | +6% |
| S&P | +13.19% | +87.83% | +13.42% | +21% |
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 94.5% |
| Market Cap | $281.57M | 366.7% |
| Market Cap / Employee | $9.39M | 0.0% |
| Employees | 30 | -41.2% |
| Net Income | -$25.18M | -55.0% |
| EBITDA | -$27.39M | -59.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $50.11M | 61.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.75M | 822.2% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.48% | 28.5% |
| Return On Invested Capital | -108.09% | 5.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.18M | -38.3% |
| Operating Free Cash Flow | -$22.12M | -37.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.00 | 0.97 | 0.11 | 1.40 | 86.39% |
| Price to Tangible Book Value | 33.26 | 33.31 | 0.11 | 1.40 | -93.75% |
| Enterprise Value to EBITDA | 0.22 | 0.93 | -2.30 | -5.24 | -423.15% |
| Return on Equity | -74.9% | -59.0% | -38.1% | -50.2% | -38.79% |
| Total Debt | $0.42M | $0.31M | $0.79M | $0.75M | 38.33% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
